Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novartis's oral MS drug fingolimod shows first Phase III efficacy

This article was originally published in Scrip

Executive Summary

Novartishas released positive data from the first Phase III trial of its novel oral multiple sclerosis therapy fingolimod (FTY720), showing that it led to a lower relapse rate than Biogen Idec's injectable drug Avonex (interferon beta-1a) a standard of care in the disease. However, the safety concerns which have troubled the drug in earlier trials, including skin cancer, remained a worry in the trial.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts